Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Anti-Cancer Drugs|March 10, 1998
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative GroupR Paridaens, J A Roy, M Nooij, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 15, 2016
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK AuditJ King, D H Palmer, P Johnson, et al.
Breast Cancer Research and Treatment|March 12, 2011
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancerR Coleman, E Woodward, J Brown, et al.
ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.
ESMO Open|August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trialD Melisi, T Macarulla, C De La Fouchardière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trialA N Serafini, S J Houston, I Resche, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2018
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinomaG K Abou-Alfa, S Qin, B-Y Ryoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 3